ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties

CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ghiglieri, Alberto, Messina, Monica, Cenacchi, Valentina, Piutti, Claudia, Cinato, Flavio, Brogin, Giandomenico, Puccini, Paola
Format: Dataset
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Ghiglieri, Alberto
Messina, Monica
Cenacchi, Valentina
Piutti, Claudia
Cinato, Flavio
Brogin, Giandomenico
Puccini, Paola
description CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration.A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference.CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile.The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions.No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species. CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration. A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference. CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile. The major metaboli
doi_str_mv 10.6084/m9.figshare.23684152
format Dataset
fullrecord <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_23684152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_23684152</sourcerecordid><originalsourceid>FETCH-LOGICAL-d912-84dbcf8f78c7dad9f8199e3761b8a282ffdf1bdc9d889403330eb709fdcc4b873</originalsourceid><addsrcrecordid>eNpNkMFKw0AYhHPxINU38PAfFUzNZmOye4y1tUKDl97Dv7v_tgtJNmy2gk8jPosvpsUWPM3AwMzwJckNy-ZlJoqHXs6t2017DDTPeSkK9phfJl_1c7OEMfiRQnQ0gbewWK9KXpb3gDD4d-pAudQeBh2dH7CDhkN_mDQGNzgNgTSN0QfAIeLOD26Kv9bA92cOaAIN_pyfwtumfqrvIKBxvkNFXUcGMILycQ__Znrv6PjoKrmw2E10fdJZsl0tt4t1unl7eV3Um9RIlqeiMEpbYSuhK4NGWsGkJF6VTAnMRW6tsUwZLY0Qssg45xmpKpPWaF0oUfFZUvzVGoyoXaR2DK7H8NGyrD0CbHvZngG2Z4D8BwNdb7E</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>dataset</recordtype></control><display><type>dataset</type><title>ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties</title><source>DataCite</source><creator>Ghiglieri, Alberto ; Messina, Monica ; Cenacchi, Valentina ; Piutti, Claudia ; Cinato, Flavio ; Brogin, Giandomenico ; Puccini, Paola</creator><creatorcontrib>Ghiglieri, Alberto ; Messina, Monica ; Cenacchi, Valentina ; Piutti, Claudia ; Cinato, Flavio ; Brogin, Giandomenico ; Puccini, Paola</creatorcontrib><description>CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration.A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference.CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile.The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions.No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species. CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration. A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference. CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile. The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions. No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species.</description><identifier>DOI: 10.6084/m9.figshare.23684152</identifier><language>eng</language><publisher>Taylor &amp; Francis</publisher><subject>Biochemistry ; Cancer ; Cell Biology ; Chemical Sciences not elsewhere classified ; Computational Biology ; FOS: Biological sciences ; FOS: Health sciences ; Infectious Diseases ; Medicine ; Microbiology ; Pharmacology ; Physiology</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,1894</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.23684152$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Ghiglieri, Alberto</creatorcontrib><creatorcontrib>Messina, Monica</creatorcontrib><creatorcontrib>Cenacchi, Valentina</creatorcontrib><creatorcontrib>Piutti, Claudia</creatorcontrib><creatorcontrib>Cinato, Flavio</creatorcontrib><creatorcontrib>Brogin, Giandomenico</creatorcontrib><creatorcontrib>Puccini, Paola</creatorcontrib><title>ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties</title><description>CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration.A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference.CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile.The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions.No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species. CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration. A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference. CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile. The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions. No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species.</description><subject>Biochemistry</subject><subject>Cancer</subject><subject>Cell Biology</subject><subject>Chemical Sciences not elsewhere classified</subject><subject>Computational Biology</subject><subject>FOS: Biological sciences</subject><subject>FOS: Health sciences</subject><subject>Infectious Diseases</subject><subject>Medicine</subject><subject>Microbiology</subject><subject>Pharmacology</subject><subject>Physiology</subject><fulltext>true</fulltext><rsrctype>dataset</rsrctype><creationdate>2023</creationdate><recordtype>dataset</recordtype><sourceid>PQ8</sourceid><recordid>eNpNkMFKw0AYhHPxINU38PAfFUzNZmOye4y1tUKDl97Dv7v_tgtJNmy2gk8jPosvpsUWPM3AwMzwJckNy-ZlJoqHXs6t2017DDTPeSkK9phfJl_1c7OEMfiRQnQ0gbewWK9KXpb3gDD4d-pAudQeBh2dH7CDhkN_mDQGNzgNgTSN0QfAIeLOD26Kv9bA92cOaAIN_pyfwtumfqrvIKBxvkNFXUcGMILycQ__Znrv6PjoKrmw2E10fdJZsl0tt4t1unl7eV3Um9RIlqeiMEpbYSuhK4NGWsGkJF6VTAnMRW6tsUwZLY0Qssg45xmpKpPWaF0oUfFZUvzVGoyoXaR2DK7H8NGyrD0CbHvZngG2Z4D8BwNdb7E</recordid><startdate>20230714</startdate><enddate>20230714</enddate><creator>Ghiglieri, Alberto</creator><creator>Messina, Monica</creator><creator>Cenacchi, Valentina</creator><creator>Piutti, Claudia</creator><creator>Cinato, Flavio</creator><creator>Brogin, Giandomenico</creator><creator>Puccini, Paola</creator><general>Taylor &amp; Francis</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20230714</creationdate><title>ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties</title><author>Ghiglieri, Alberto ; Messina, Monica ; Cenacchi, Valentina ; Piutti, Claudia ; Cinato, Flavio ; Brogin, Giandomenico ; Puccini, Paola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d912-84dbcf8f78c7dad9f8199e3761b8a282ffdf1bdc9d889403330eb709fdcc4b873</frbrgroupid><rsrctype>datasets</rsrctype><prefilter>datasets</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biochemistry</topic><topic>Cancer</topic><topic>Cell Biology</topic><topic>Chemical Sciences not elsewhere classified</topic><topic>Computational Biology</topic><topic>FOS: Biological sciences</topic><topic>FOS: Health sciences</topic><topic>Infectious Diseases</topic><topic>Medicine</topic><topic>Microbiology</topic><topic>Pharmacology</topic><topic>Physiology</topic><toplevel>online_resources</toplevel><creatorcontrib>Ghiglieri, Alberto</creatorcontrib><creatorcontrib>Messina, Monica</creatorcontrib><creatorcontrib>Cenacchi, Valentina</creatorcontrib><creatorcontrib>Piutti, Claudia</creatorcontrib><creatorcontrib>Cinato, Flavio</creatorcontrib><creatorcontrib>Brogin, Giandomenico</creatorcontrib><creatorcontrib>Puccini, Paola</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Ghiglieri, Alberto</au><au>Messina, Monica</au><au>Cenacchi, Valentina</au><au>Piutti, Claudia</au><au>Cinato, Flavio</au><au>Brogin, Giandomenico</au><au>Puccini, Paola</au><format>book</format><genre>unknown</genre><ristype>DATA</ristype><title>ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties</title><date>2023-07-14</date><risdate>2023</risdate><abstract>CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration.A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference.CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile.The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions.No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species. CHF6366, a dual action β2-receptor agonist and M3-muscarinic receptor antagonist developed for chronic obstructive pulmonary disease (COPD) was [14C]-radiolabelled on the two different functional moieties of the molecule (either aminobutanolic or carbamate) to characterise its ADME profile following intravenous (IV), intratracheal (IT) and oral (PO) administration. A very low oral bioavailability and a good balance between absorption and lung retention after IT administration were observed, together with a rapid distribution throughout the body and a complete metabolic transformation of the parent drug without relevant gender difference. CHF6366 was observed fully hydrolysed to alcohol (CHF6387) and carboxylic acid (CHF6361) in plasma and urine after IV and IT administration, and mainly unchanged in faeces only after oral administration. An important number of metabolites containing aminobutanolic moiety was excreted via urine, whereas carbamate-containing derivatives were excreted mainly by bile. The major metabolic routes of the alcoholic moiety (CHF6387) included isomerisation (Ma7), conjugation with glucuronic acid and dehydrogenation, while the carboxylic acid moiety (CHF6361) was mainly metabolised through oxidation, glucuronide conjugation and, in both pathways, combinations of those metabolic reactions. No major differences arose also from in vitro metabolism profiles investigated using liver microsomes and hepatocytes of different species.</abstract><pub>Taylor &amp; Francis</pub><doi>10.6084/m9.figshare.23684152</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier DOI: 10.6084/m9.figshare.23684152
ispartof
issn
language eng
recordid cdi_datacite_primary_10_6084_m9_figshare_23684152
source DataCite
subjects Biochemistry
Cancer
Cell Biology
Chemical Sciences not elsewhere classified
Computational Biology
FOS: Biological sciences
FOS: Health sciences
Infectious Diseases
Medicine
Microbiology
Pharmacology
Physiology
title ADME properties of CHF6366, a novel bi-functional M3 muscarinic receptor antagonist and ß2 adrenoceptor agonist (MABA) radiolabelled at both functional moieties
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A58%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Ghiglieri,%20Alberto&rft.date=2023-07-14&rft_id=info:doi/10.6084/m9.figshare.23684152&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_23684152%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true